Form 4: Apellis Pharmaceuticals' Chief Technical Officer, Nur Nicholson, Sells Shares

Nur Nicholson, Chief Technical Officer of Apellis Pharmaceuticals, sold a total of 11,220 shares of common stock in multiple transactions on March 13, 2024.

Summary

• On March 13, 2024, Nur Nicholson, the Chief Technical Officer of Apellis Pharmaceuticals, executed multiple sales of the company's common stock.
• A total of 7,768 shares were sold at a weighted average price of $57.307, with individual trades ranging from $56.91 to $57.75.
• An additional 3,452 shares were sold at a weighted average price of $58.1335, with individual trades ranging from $57.92 to $58.34.
• Following these transactions, Nicholson directly owns 56,287 shares of Apellis Pharmaceuticals' common stock.

Sentiment

Score: 5

Explanation: This is a neutral document, simply reporting stock sales by an officer. The sentiment is neither positive nor negative without additional context.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It's important to monitor such filings to understand management's perspective on the company's stock and future prospects. However, without additional context, it's difficult to determine the specific reasons behind the stock sale.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, depending on how it's perceived by the market.
• The impact on employees, customers, suppliers, and creditors is likely to be negligible.

Key Dates